Predictive value of bone scans in an adjuvant breast cancer program.
Technetium 99m phosphate-complex bone scans were performed in 43 women within two months of mastectomy for stage I (1 patient), stage II (28 patients), and stage III (14 patients) breast cancer. Twelve (28%) initial bone scans were interpreted as either equivocally abnormal (6 scans) or definitely abnormal (6 scans). Radiographs confirmed metastatic disease in 2 patients who were then considered ineligible for adjuvant therapy (adriamycin-cyclophosphamide with or without local radiotherapy). Of the remaining 41 eligible patients, all have received adjuvant therapy and 36 have had at least one additional bone scan at 6-month intervals. Among 20 patients whose serial bone scans were unchanged, there has been no clinical recurrence with a mean followup of 20 months. In contrast, among 16 patients whose serial bone scans have changed (e.g., appearance of new focal lesions, disappearance of old lesions), there have been 6 clinical recurrences (p = 0.01) with a mean followup of 43 months. We conclude that carefully performed technetium pyrophosphate bone scans are helpful in the accurate initial staging of patients being considered for adjuvant breat cancer treatment, and that serial changes in the bone scan identify a group of patients at high risk for early recurrence.